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a b s t r a c t
The prevalence of metabolic syndrome persistently increases and affects over 30% of U.S. adults. To study
how metabolic syndrome may induce tubulointerstitial injury and whether acetaminophen has renal-
protective properties, 4-week-old obese Zucker rats were randomly assigned into three groups, control
(OC), vehicle dimethyl sulfoxide (OV), and acetaminophen treatment (30 mg/kg/day for 26 weeks),
and lean Zucker rats served as healthy controls. Signiﬁcant tubulointerstitial injuries were observed in
both OC and OV animals, evidenced by increased tubular cell death, tubular atrophy/dilation,
inﬂammatory cell inﬁltration, and ﬁbrosis. These tubulointerstitial alterations were signiﬁcantly reduced
by treatment with a chronic but low dose of acetaminophen, which acted to diminish NADPH oxidase
isoforms Nox2 and Nox4 and decrease tubulointerstitial oxidative stress (reduced tissue superoxide and
macromolecular oxidation). Decreased oxidative stress by acetaminophen was paralleled by the
reduction of tubular proapoptotic signaling (diminished Bax/Bcl-2 ratio and caspase 3 activation) and
the alleviation of tubular epithelial-to-mesenchymal transition (decreased transforming growth factor β,
connective tissue growth factor, α-smooth muscle actin, and laminin). These data suggest that increased
oxidative stress plays a critical role in mediating metabolic syndrome-induced tubulointerstitial injury
and provide the ﬁrst evidence suggesting that acetaminophen may be of therapeutic beneﬁt for the
prevention of tubulointerstitial injury.
& 2013 The Authors. Published by Elsevier Inc.
Introduction
Metabolic syndrome is characterized by the development of abdo-
minal obesity, insulin resistance, dyslipidemia, and hypertension [1].
The incidence of this disorder is increasing rapidly worldwide and
it afﬂicts over 34% of U.S. adults [2,3]. If not properly managed,
metabolic syndrome can cause renal damage, which can progress
to the development of chronic kidney disease (CKD) and end-stage
renal disease (ESRD), which requires dialysis treatment and
ultimately kidney transplantation [4,5]. The pathological progres-
sion of CKD to ESRD includes gradual glomerulosclerosis, tubular
atrophy/dilation, inﬂammatory cell inﬁltration, and interstitial
ﬁbrosis [6]. It is thought that these tubulointerstitial injuries
contribute signiﬁcantly to the development of CKD [7] and that
the degree of interstitial ﬁbrosis is a predictor for the progression
to ESRD [8]. To our knowledge, the molecular mechanism
(s) regulating tubulointerstitial injury in metabolic syndrome
remains to be elucidated.
Accumulating evidence has suggested that elevations in tissue
oxidative stress may play a pivotal role in the initiation and
progression of kidney disease [1,9]. Nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidase (Nox) is thought to be one of the
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major sources of superoxide generation, and excessive superoxide
production has been shown to cause cell apoptosis and ﬁbrosis
[9,10]. Acetaminophen (N-acetyl-p-aminophenol, APAP) is a widely
used over-the-counter analgesic and antipyretic drug [11]. Recent
studies from our laboratory and others have shown that acetami-
nophen exhibits strong antioxidant properties in a number of
biological systems and that this drug can prevent oxidative stress-
induced tissue damage [12–18]. Whether acetaminophen treatment
can diminish the development of tubulointerstitial injury during
the progression of metabolic syndrome has, to our knowledge, not
been investigated. Herein, we investigate how oxidative stress may
contribute to the pathogenesis of tubulointerstitial damage and
whether and how acetaminophen may affect the development of
renal remodeling in metabolic syndrome. Our ﬁndings demonstrate
that increased oxidative stress can activate the tubular cell death
pathway, stimulate tubular epithelial-to-mesenchymal transition,
and hence cause tubulointerstitial injury in metabolic syndrome
animals. Our data also suggest that chronic acetaminophen admin-
istration may be useful for preventing some of the renal damage
seen in metabolic syndrome.
Materials and methods
Materials
Acetaminophen (A5000), dimethyl sulfoxide (DMSO; D8418), and
β-N-acetylglucosaminidase (NAG) assay kit (CS0780) were purchased
from Sigma–Aldrich (St. Louis, MO, USA). Creatinine enzyme-linked
immunosorbent assay (ELISA) kit (500701) was from Cayman Che-
mical (Ann Arbor, MI, USA). Hematoxylin (s212) and eosin (s2186;
H&E) were from Poly Scientiﬁc R&D Corp. (Bay Shore, NY, USA).
Formaldehyde (18814) and Picro-sirius red (PSR) stain kit (24901)
were from Polysciences (Warrington, PA, USA). Dihydroethidium
(DHE; D23107) was from Molecular Probes (Eugene, OR, USA).
Terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) apoptosis detection kit (11684795910) was from Roche
Applied Science (Indianapolis, IN, USA). OxyBlot protein oxidation
detection kit (S7150) was fromMillipore (Billerica, MA, USA). Primary
antibodies (caspase 3 (9662), cleaved caspase 3 (9661), Bax (2772),
Bcl-2 (2876), glyceraldehyde-3-phosphate dehydrogenase (2118;
GAPDH)), horseradish peroxidase-linked anti-biotin antibody
(7075)) and biotinylated protein ladder (7277) were from Cell
Signaling Technology (Danvers, MA, USA). Antibodies against ED1
(ab31630), CD5 (ab22356), transforming growth factor β (TGF-β;
ab66043), connective tissue growth factor (CTGF; ab6992), α-smooth
muscle actin (α-SMA; ab5694), laminin (ab11575), 4-hydroxynonenal
(4-HNE; ab46545), and Nox2 (ab31092) were from Abcam (Cam-
bridge, MA, USA). Nox4 (sc30141) and 8-hydroxydeoxyguanosine (8-
OHdG; sc130085) antibodies were from Santa Cruz Biotechnology
(Dallas, TX, USA). Texas-red-labeled goat anti-mouse IgG (TI-2000),
ﬂuorescein-labeled goat anti-rabbit IgG (FI-1000), and ﬂuorescence
mounting medium with DAPI (H-1200) were from Vector Labora-
tories (Burlingame, CA, USA). ECLWestern blotting detection reagents
(RPN2106) were from GE Healthcare Life Sciences (Pittsburgh, PA,
USA). Other chemicals used in this study were purchased from
Sigma–Aldrich.
Animals and experimental treatment
Animal studies were conducted with the approval of the Institu-
tional Animal Care and Use Committee at Marshall University. Male
obese and lean Zucker rats were purchased from Charles River
Laboratories (Wilmington, MA, USA) at 3 weeks of age, housed
in individual cages (two rats each) under controlled temperature
(22 1C) and humidity (50%) with a 12:12-h light:dark cycle, and
fed standard rat chow and tap water ad libitum. After a week for
environmental acclimation, obese Zucker rats were randomly assigned
into three groups (n¼6 each): obese control (OC), obese vehicle (OV;
0.073 ml DMSO/kg/day), and obese treated with acetaminophen (OT;
acetaminophen was dissolved in DMSO, 30 mg APAP/kg/day via
drinking water for 26 weeks). Age-matched lean Zucker rats were
used as controls (LC; n¼6).
Urine samples and renal tissue collection
At the end of the experiment (30 weeks of age), animals were
subjected to intraperitoneal administration of a ketamine:xylazine
cocktail (3.5:1; 1 ml/kg) and supplemented as necessary for reﬂexive
response before tissue collection. Urine was directly collected via
bladder puncture and then centrifuged at 2000g for 5 min. The
supernatant was stored at 80 1C until assayed. Kidneys were
removed, snap-frozen in liquid nitrogen, and stored at 80 1C for
analysis.
Evaluation of urinary NAG activity
Urine NAG activity was determined by a NAG assay kit follow-
ing the manufacturer's protocol. To control the variations in
urinary concentration (which is related to urine volume) between
animals, the NAG activity was further normalized to urine creati-
nine concentration and expressed as NAG/creatinine ratio for each
individual animal. Urine creatinine concentrations were measured
using the ELISA kit according to the manufacturer's protocol.
Evaluation of tubulointerstitial damage
Tubulointerstitial damage was evaluated by H&E and PSR stain-
ing. Brieﬂy, renal tissue samples were serially sectioned (8 mm) and
then stained with H&E and PSR as directed by the manufacturers.
Tubulointerstitial damage was graded based on the degree of tubular
atrophy or dilatation, cell inﬁltration, and ﬁbrosis as follows: 0,
normal; grade 1, o10%; grade 2, 10–25%; grade 3, 25–50%; grade
4, 50–75%; grade 5, 75–100% of affected area [19]. At least 30 random
ﬁelds at 200 magniﬁcation for each animal were evaluated. Tissue
staining and analysis were done in a blinded fashion.
Immunoﬂuorescence
To determine the expression and spatial distribution of key
molecular mediators and the role of cellular inﬁltration during renal
remodeling, biomarkers, including CD5, ED1, TGF-β, CTGF, α-SMA,
4-HNE and 8-OHdG, were detected using immunoﬂuorescence as
described previously [16,17,20]. The nuclei were counterstained with
DAPI, which was present in the ﬂuorescence mounting medium.
TUNEL assay
DNA fragmentation was determined using an In Situ Cell Death
Detection Kit (TUNEL) as described previously [17,20]. Cell nuclei
were visualized with DAPI staining. Images of 30 random ﬁelds of
each animal were taken using an Olympus BX51 ﬂuorescence
microscope (Olympus America, Melville, NY, USA) at 200 mag-
niﬁcation, and TUNEL-positive apoptotic nuclei were counted.
Immunoblotting
Total protein extracts were prepared and immunoblotting was
performed as previously described [16]. Primary antibodies included
anti-caspase 3, anti-cleaved caspase 3 (active form), anti-Bax, anti-Bcl-
2, anti-TGF-β, anti-CTGF, anti-laminin, anti-α-SMA, anti-Nox2, and
anti-Nox4.
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Evaluation of protein oxidation
Oxidized proteins were assayed with an OxyBlot Oxidized
Protein Detection Kit as previously described [18].
Reactive oxygen species (ROS) detection
The ﬂuorescent dye DHE was used to measure the superoxide
production in kidney as described earlier [15]. Fluorescence was
visualized using an Olympus BX51 ﬂuorescence microscope
(Olympus America, Melville, NY, USA). The ﬂuorescence intensity
in tubulointerstitium was quantiﬁed using ImageJ software.
Statistical analysis
Quantitative results are expressed as the mean7standard error
of mean (SEM). Data were analyzed using the SAS GLM procedure
(SAS Institute, Inc., Cary, NC, USA), and multiple comparisons using
the Newman–Keuls method were performed to determine differ-
ences between groups. Results were considered signiﬁcant when
Pr0.05.
Results
Tubulointerstitial lesions in obese Zucker rats
Compared to LC animals, kidneys from both OC and OV rats
exhibited visible tubulointerstitial damage, including local and
focal areas of tubular atrophy or dilation, cell inﬁltration, and
interstitial ﬁbrosis (Fig. 1). The tubulointerstitial damage score, which
encompasses measures of tubular atrophy/dilation, cell inﬁltration,
and interstitial ﬁbrosis [19], was signiﬁcantly higher in the OC and OV
animals than in the LC animals (þ8.5- and þ8.1-fold, respectively;
Fig. 1). These structural damages were signiﬁcantly reduced in the
acetaminophen-treated Zucker animals (60.9% compared to OV;
Po0.05; Fig. 1).
Inﬂammatory cell inﬁltration in tubulointerstitium of obese Zucker
rats
To examine whether inﬂammatory cells are involved in cell
inﬁltration, the presence of macrophages and lymphocytes in
tubulointerstitium was detected using the speciﬁc biomarkers
ED1 and CD5, respectively [19]. The number of tubulointerstitial
macrophages (ED1/DAPI-positive cells) was increased by 7.5- and
8.4-fold in the OC and OV animals, respectively, compared to the
lean controls (Figs. 2A and C; Pr0.05), but reduced after acet-
aminophen treatment (60.0% compared to OV; Pr0.05; Figs. 2A
and C). Similar ﬁndings were seen in the tubulointerstitial inﬁltra-
tion of lymphocytes (CD5/DAPI-positive cells; þ7.5- and þ7.4-fold
in OC and OV compared to LC and 73.7% in OT compared to OV
rats; Pr0.05; Figs. 2B and D).
Urinary NAG content in obese Zucker rats
Urinary NAG, a lysosomal enzyme primarily originating from the
proximal tubule, is indicative of renal tubular cell breakdown [21,22].
To evaluate whether the elevated tubulointerstitial damage score in
obese Zucker animals and its reduction by acetaminophen were
physiologically signiﬁcant, urinary NAG activity was determined.
As shown in Fig. 3, urinary NAG activity (normalized to urine
Fig. 1. Tubulointerstitial lesions in obese Zucker rats. Frozen kidney sections were stained with H&E and PSR. Images were captured at 200 original magniﬁcation. The
severity of tubulointerstitial injury was evaluated by damage scores based on the degree of tubular atrophy or dilatation, cell inﬁltration, and ﬁbrosis, as described under
Materials and methods. Data are expressed as the mean7SEM (n¼6). LC, lean Zucker control rats; OC, obese Zucker control rats; OV, obese Zucker rats treated with vehicle
(DMSO); OT, obese Zucker rats treated with acetaminophen (30 mg/kg/day) for 26 weeks. Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05).
Scale bar, 100 μm.
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Fig. 2. Inﬂammatory cell inﬁltration in tubulointerstitium of obese Zucker rats. (A) Tubulointerstitial inﬁltration of macrophages (indicated by arrows and enlarged insets)
was detected via immunoﬂuorescence using speciﬁc ED1 antibody, and (C) the number of ED1-positive cells/mm2 was counted. (B) Tubulointerstitial inﬁltration of
lymphocytes (indicated by arrows and enlarged insets) was detected via immunoﬂuorescence using CD5 antibody, and (D) the number of CD5-positive cells/mm2 was
counted. Data are expressed as the mean7SEM (n¼6). Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05). Scale bar, 50 μm.
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creatinine) in OC and OV animals was higher than that in LC
animals (þ2.0- and þ2.1-fold, respectively; Pr0.05). Similar to
the ﬁnding of reduced tubulointerstitial damage score, acetami-
nophen treatment decreased urinary NAG activity in obese animal
(41.1% compared to OV; Po0.05; Fig. 3).
Tubulointerstitial cell apoptosis in obese Zucker rats
To examine the potential role of apoptosis in the pathogenesis of
tubulointerstitial damage, tubular cell apoptosis was detected by
TUNEL staining. As shown in Fig. 4A, the number of TUNEL-positive
cells (both TUNEL- and DAPI-positively stained, which indicates
nuclear DNA fragmentation) in the tubules of obese Zucker animals
was higher compared to the lean controls (þ13.7- and þ14.1-fold,
respectively; Pr0.05), whereas it was reduced after acetaminophen
treatment (67.0% compared to OV; Pr0.05; Fig. 4A).
To assess whether the balance of renal proapoptotic protein
Bax and antiapoptotic protein Bcl-2 was affected by metabolic
syndrome, the expression of Bax and Bcl-2 proteins was measured
using immunoblotting. As shown in Fig. 4B, the expression of Bcl-2
protein was signiﬁcantly decreased in obese Zucker control and
vehicle rats (Pr0.05), whereas acetaminophen treatment was
able to restore Bcl-2 protein content to that comparable to the
lean control. The expression of Bax protein was not different
among the four groups. Further analysis of the Bax/Bcl-2 ratio,
an index of proapoptotic signaling pathway activation [23],
demonstrated that the Bax/Bcl-2 ratio was higher in both obese
control and vehicle rats compared to the lean control (þ66.7 and
þ60.5%, respectively; Pr0.05; Fig. 4B). Acetaminophen treatment
signiﬁcantly decreased the Bax/Bcl-2 ratio in the obese Zucker
kidney (25.8% compared to OV; Pr0.05; Fig. 4B).
Fig. 3. Urinary NAG activity in obese Zucker rats. The enzyme activity of NAG and
the concentration of creatinine in urine were measured as described under
Materials and methods. The activity of NAG was normalized to the concentration
of creatinine of the same animal. Each column represents the mean7SEM (n¼6).
Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05).
Fig. 4. Tubulointerstitial cell apoptosis in obese Zucker rats. (A) Nuclear DNA fragmentation was detected using TUNEL staining, and TUNEL-positive cells (indicated by
arrows) were counted. Scale bar, 100 μm. (B) The expression of Bax and Bcl-2 in kidneys was detected by immunoblotting, and the ratio of Bax/Bcl-2 of each animal was
calculated and normalized to GAPDH. (C) The expression of caspase 3 (full length (35 kDa) and cleaved fragments (17 and 19 kDa)) was detected by immunoblotting.
Each column represents the mean7SEM (n¼6). Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05).
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Fig. 5. The epithelial-to-mesenchymal transition-like changes in tubulointerstitium of obese Zucker rats. (A) Representative images (original magniﬁcation 400 ) of
tubulointerstitial α-SMA immunoﬂuorescence staining (green ﬂuorescent signal). Arrows indicate tubular cells expressing α-SMA. (B) Renal α-SMA expression was detected
by immunoblotting. (C) Expression of renal laminin, a major component of the ECM, was analyzed by immunoblotting. (D and E) Representative images (original
magniﬁcation 400 ) of tubulointerstitial TGF-β (D) and CTGF (E) immunoﬂuorescence staining (green ﬂuorescent signal) to show the spatial expression/distribution of
TGF-β and CTGF proteins. Scale bar, 50 μm. (F and G) Renal expression of TGF-β (F) and CTGF (G) was measured by Western blot. Each column represents the mean7SEM
(n¼6). Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05). (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
C. Wang et al. / Free Radical Biology and Medicine 65 (2013) 1417–14261422
It has been shown that caspase 3 plays an important role
in the execution phase of apoptosis [24]. The abundance of total
caspase 3 (35 kDa) was not different between lean and obese
Zucker animals. However, the amount of cleaved (active) form of
caspase 3 (19 and 17 kDa) was signiﬁcantly increased in obese
Zucker rats (þ141.2 and þ121.3% for 19 kDa and þ60.2 and
þ47.3% for 17 kDa, respectively; Pr0.05; Fig. 4C), whereas both
cleaved fragments were decreased after acetaminophen treat-
ment (42.6% for 19 kDa and 36.5% for 17 kDa compared to
OV; Pr0.05; Fig. 4C).
Fig. 6. Tubulointerstitial oxidative stress in obese Zucker rats. (A) The level of tubulointerstitial superoxides (red ﬂuorescent signal) was measured by DHE staining
(representative images, 200 original magniﬁcation). Scale bar, 100 μm. (B) Lipid peroxidation was detected by immunoﬂuorescence with 4-HNE antibody (400 original
magniﬁcation), and the relative abundance (green ﬂuorescent signal) was quantiﬁed. Scale bar, 50 μm. (C) DNA oxidation was detected by immunoﬂuorescence with 8-OHdG
antibody (400 original magniﬁcation), and the relative abundance was quantiﬁed. Scale bar, 50 μm. (D) Protein oxidation was analyzed by OxyBlot. Each column represents
the mean7SEM (n¼6). Groups without the same letter (a or b) are signiﬁcantly different (Pr0.05). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Epithelial-to-mesenchymal transition (EMT)-like changes in
tubulointerstitium of obese Zucker rats
It is considered that EMT or EMT-like changes (also known as
epithelial phenotypic changes) are an important mechanism
mediating renal tubulointerstitial ﬁbrosis [25–27]. To determine
whether EMT mechanisms are involved in the pathogenesis of
tubulointerstitial damage, and whether acetaminophen can
attenuate tubular EMT in obese Zucker rats, the expression and
spatial distribution of tubulointerstitial α-SMA (a biomarker of
EMT [28]) and laminin (a major component of extracellular matrix
(ECM) [29]) were examined by immunoﬂuorescence and immu-
noblotting. The expression of α-SMA protein in the tubular and
interstitial cells from lean control animals was relatively low
(Fig. 5A). Conversely, the ﬂuorescence intensity of α-SMA was
visibly increased in both tubular and interstitial cells of the obese
Zucker animals, whereas it was signiﬁcantly reduced after acet-
aminophen treatment (Fig. 5A). These ﬁndings were further
conﬁrmed by immunoblotting analysis (Fig. 5B). In support of
the α-SMA ﬁndings, the expression of laminin protein was
signiﬁcantly higher in the OC and OV rats compared to the LC rats
(Pr0.05), and it was signiﬁcantly reduced after acetaminophen
treatment (Pr0.05; Fig. 5C).
TGF-β plays a critical role in mediating the ﬁbrotic remodeling
in kidney disease, and can induce ECM protein expression either
directly or together with CTGF [30,31]. To further determine
whether these signaling molecules were involved in renal ﬁbrotic
remodeling in the obese Zucker rats, the expression and spatial
distribution of TGF-β and CTGF in the tubulointerstitium were also
evaluated via immunoﬂuorescence. Similar to that observed for
α-SMA, the ﬂuorescence intensity of both TGF-β and CTGF was
lower in the lean control animals, and acetaminophen treatment
prevented the increased expression of TGF-β and CTGF protein in
the tubulointerstitium of the obese Zucker rats (Figs. 5D and E).
These changes were further conﬁrmed by Western blot (Pr0.05;
Figs. 5F and G).
Tubulointerstitial oxidative stress in obese Zucker rats
Accumulating evidence has suggested that the overproduction
of ROS plays a key role in mediating the pathogenesis of metabolic
syndrome [1,32]. To determine if increased oxidative stress is
involved in the pathogenesis of tubulointerstitial damage, renal
superoxide levels were assessed using DHE staining. Compared
with lean control rats, superoxide levels were higher in obese
Zucker control and vehicle rats (þ1.7- and þ1.6-fold, respectively;
Pr0.05; Fig. 6A). Acetaminophen treatment restored tubulointer-
stitial superoxide in obese Zucker rats to a level comparable to the
lean control (Fig. 6A). Supporting these ﬁndings, lipid peroxidation
(4-HNE staining; Fig. 6B), DNA oxidation (8-OHdG staining;
Fig. 6C), and protein oxidation (OxyBlot; Fig. 6D) were dramatically
elevated in obese control and vehicle rats but signiﬁcantly reduced
with acetaminophen treatment (Pr0.05).
Expression of NADPH oxidase isoforms in obese Zucker rats
The NADPH oxidase is one of the major sources of renal ROS
production, and Nox2 and Nox4 are the two major isoforms of its
catalytic subunit expressed in the kidney [33–35]. The amount of
glycosylated Nox2 (91 kDa, mature form) in the obese control and
vehicle rats was increased compared to that observed in the lean
control animals (þ1.2- and þ1.0-fold, respectively; Pr0.05;
Fig. 7A), but attenuated with chronic acetaminophen treatment
(32.0% compared to OV; Pr0.05; Fig. 7A). There was no
difference in nonglycosylated Nox2 (55 kDa, immature form)
among the four groups (P¼0.7; Fig. 7A). Similarly, the expression
of Nox4 was signiﬁcantly increased in OC and OV rats but
diminished by acetaminophen treatment (þ1.2-fold for both OC
and OV compared to LC, and 28.0% in OT compared to OV;
Pr0.05; Fig. 7B).
Discussion
Metabolic syndrome is a signiﬁcant risk factor for the development
of kidney disease that affects over 70 million American adults [2–4].
Using the obese Zucker (Leprfa/fa) rat model of metabolic syndrome,
which is thought to closely mimic the progression and pathology of
metabolic syndrome seen in humans [36,37], we observed signiﬁcant
evidence of tubulointerstitial injury in the 30-week-old animals,
including inﬂammatory cell inﬁltration, tubular atrophy/dilation,
and ﬁbrosis. Importantly, we also demonstrated that acetamino-
phen intervention (30 mg/kg/day) is able to ameliorate many
Fig. 7. Expression of NADPH oxidase isoforms in the kidneys of obese Zucker rats. (A) The expression of Nox2 in kidney tissues was determined by immunoblotting. The
bands of 55 and 91 kDa represent nonglycosylated (immature form) and glycosylated Nox2 (mature form), respectively. (B) The expression of Nox4 in kidney tissues. Each
column represents the mean7SEM (n¼6). Groups without the same letter (a, b, or c) are signiﬁcantly different (Pr0.05).
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aspects of tubulointerstitial injury and that the protective effects
appear to be mediated, at least partially, through the reduction of
oxidative stress, inhibition of tubulointerstitial cell death path-
ways, and attenuation of tubular epithelial-to-mesenchymal
transition.
Although the nephropathy associated with metabolic syndrome
has been fairly well characterized in both animals and humans
[37,38], less is known regarding the mechanism(s) responsible for
this damage. Given recent reports suggesting that oxidative stress is
signiﬁcantly increased in obesity, type 2 diabetes, dyslipidemia, and
hypertension [32,39,40], we posited that increased oxidative stress
might also mediate nephropathy and stimulate tubulointerstitial
damage in metabolic syndrome. Our ﬁndings of increased tubu-
lointerstitial superoxide in the obese Zucker rat support this
contention (Fig. 6A) and are consistent with the increased oxidation
of macromolecules observed in the tubulointerstitium (Figs. 6B–D).
Acetaminophen is a widely used analgesic and antipyretic [11]
and is suggested to possess potent antioxidant activity [12–16].
Whether acetaminophen treatment can decrease the oxidative
stress and prevent the tubulointerstitial damage seen in metabolic
syndrome is currently unknown. Given recent ﬁnding that the
obese Zucker rat develops metabolic syndrome as early as 1 month
of age [38,41], we initiated acetaminophen intervention when the
animals were 4 weeks of age. On the basis of our previous study
using F344BN rats, in which acetaminophen at the dose of 30 mg/
kg/day for 6 months was able to improve cardiac and skeletal
muscle structure and function [15–18], we chose the same dose of
acetaminophen for the current study. Consistent with our previous
work demonstrating that acetaminophen could decrease super-
oxide levels in aged skeletal muscle and heart [15,18], we found
that acetaminophen treatment for 26 weeks diminished tubuloin-
terstitial superoxide levels and the amount of renal lipid, DNA, and
protein oxidation in the obese Zucker rat (Fig. 6). Future dose–
response studies will be invaluable in further deﬁning the ther-
apeutic window and efﬁcacy of acetaminophen use.
It is thought that elevated NADPH oxidase is a major source of
ROS production [10,34]. Accumulating evidence has also suggested
that the expression of NADPH oxidase is enhanced in the diabetic
kidney and that inhibition of NADPH oxidase reduces oxidative
stress and diabetes-associated renal injury [33]. Recent studies
have also shown that the NADPH oxidase isoforms Nox2 and Nox4
are involved in the pathogenesis of kidney disease [33,35,42].
Nonetheless, whether the reduced oxidative stress by acetamino-
phen is mediated by these enzymes has, to our knowledge, not
been reported. Consistent with our measurement of decreased
tubulointerstitial superoxide levels with acetaminophen treat-
ment, we found that the increased glycosylated Nox2 and Nox4
expression in the obese Zucker kidney was diminished with
acetaminophen treatment (Fig. 7), suggesting that acetaminophen
may target Nox2 and Nox4 and hence reduce oxidative stress.
However, how acetaminophen can affect the expression and
glycosylation/maturation of these enzymes and what type of renal
cell population is involved remain to be further investigated.
It is well known that excessive levels of oxidative stress can
stimulate cell death and that this process is mediated, at least in
part, by the increased Bax/Bcl-2 ratio and the eventual activation
of caspase 3 [23,24]. Supporting this hypothesis, we found that the
increased tubulointerstitial oxidative stress seen in obese Zucker
rats (Fig. 6) was associated with decreased Bcl-2 expression,
elevated Bax/Bcl-2 ratio (Fig. 4B), increased caspase 3 activation
(Fig. 4C), and, importantly, increased nuclear DNA fragmentation
(Fig. 4A). Supporting our ﬁndings of reduced renal oxidative stress
(Fig. 6), we found that chronic acetaminophen treatment inhibited
the activation of proapoptotic pathways (Figs. 4B and C) and
tubulointerstitial cell damage (Figs. 3 and 4A). Taken together,
these data suggest that the protective effect of acetaminophen on
metabolic syndrome-induced tubulointerstitial damage is at least
partially mediated by decreased ROS and cell apoptosis.
Recent data have suggested that the tubular epithelial-to-
mesenchymal transition plays a critical role in mediating renal
tubulointerstitial ﬁbrosis in nephropathy [25–27]. Tubular EMT is
an orchestrated and highly regulated process, in which renal tubular
cells, in response to injury or insult, lose their epithelial phenotype
and take on the myoﬁbroblast-like features of mesenchymal cells
[25,26,43]. In the present study, we observed a signiﬁcant increase
in the expression of α-SMA (a molecular marker of myoﬁbroblasts
[28,44]) and laminin (a major component of ECM [29]) in the
kidneys of the obese Zucker rats and that these changes were
attenuated with chronic acetaminophen treatment (Figs. 5A–C). To
further identify how acetaminophen can attenuate tubular EMT, we
also investigated two well-known EMT regulators: TGF-β and CTGF
[30,31]. It has been shown that TGF-β and CTGF can be induced by
increased ROS levels [9,30]. Consistent with elevated oxidative
stress (Fig. 6), we found increased expression of TGF-β and CTGF
in the tubular cells of the obese Zucker rats (Figs. 5D–G), which
appeared to parallel the increased EMT (Figs. 5A–C). As expected,
chronic acetaminophen treatment functioned to prevent these
changes (Figs. 5 and 6), suggesting that decreased tubulointerstitial
ﬁbrosis by acetaminophen (Fig. 1) is likely to be mediated by
inhibition of the tubular epithelial-to-mesenchymal transition.
In summary, our results suggest that metabolic syndrome
predisposes signiﬁcantly to the pathological development of
tubulointerstitial damage, even at a young age. Increased oxidative
stress and oxidative damage to macromolecules participate in
mediating the deteriorative effect of metabolic syndrome on
tubulointerstitial injury. Our ﬁndings also provide the ﬁrst evi-
dence suggesting that acetaminophen is a potential therapeutic
agent for the prevention of the tubulointerstitial injury caused by
metabolic syndrome. Our data demonstrate that decreased tubuloin-
terstitial lesions by acetaminophen is associated with decreased
NADPH oxidases (glycosylated Nox2 and Nox4 expression) and
tubulointerstitial oxidative damage, reduced apoptotic activation and
cell death, and attenuated tubular epithelial-to-mesenchymal transi-
tion, which help to reduce tubular atrophy/dilation, cell inﬁltration,
Fig. 8. Proposed mechanisms of oxidative stress-mediated tubulointerstitial injury
in obese Zucker rats and the preventive effect of acetaminophen. Prolonged
metabolic syndrome induces overproduction of NADPH oxidase isoforms and
tubulointerstitial oxidative stress, which leads to increases in tubular cell death/
apoptosis and tubular EMT-like changes, thereby causing increased tubulointer-
stitial damages (tubular atrophy/dilation, inﬂammatory cell inﬁltration, and tubu-
lointerstitial ﬁbrosis). Acetaminophen acts to inhibit the expression and maturation
of NADPH oxidases and reduce tubulointerstitial oxidative stress, resulting in a
signiﬁcant attenuation of tubulointerstitial injury in obese Zucker rats. Red lines
indicate the deteriorative effects of metabolic syndrome (increase/activation), and
blue lines represent the protective effect of acetaminophen (decrease/inhibition).
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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and ﬁbrosis in the tubulointerstitium (Fig. 8). Additional preclini-
cal and clinical studies including dose–response to better deﬁne
the efﬁcacy of an acetaminophen intervention for the treatment of
metabolic syndrome may be warranted.
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